US Patent 4,900,755 Scope, Claim Construction, and Patent Landscape for Controlled-Release Oral Carbidopa/Levodopa Formulations
Executive summary: U.S. Patent 4,900,755 claims a specific controlled-release oral formulation of carbidopa + levodopa in a polymer vehicle made of (i) water-soluble hydroxypropylcellulose (HPC) and (ii) a less water-soluble vinyl acetate-crotonic acid copolymer, with simultaneous, slow release of both actives. The claim set is narrower than generic “controlled-release carbidopa/levodopa” because it requires tight composition constraints for both dose ranges and polymer amounts and a defined release characteristic (“slowly and simultaneously”). Enforceable claim scope is therefore strongest against formulations that use the same dual-polymer architecture and fall within the recited mass ranges.
What does US 4,900,755 claim about controlled-release carbidopa levodopa?
Claim 1 is the core independent claim. It is directed to a controlled-release oral dosage formulation with three categories of limitations: (1) actives (carbidopa/levodopa), (2) polymer vehicle identity (specific polymers), and (3) functional release behavior (slow and simultaneous release).
Claim 1 limitations (element-by-element)
A. Dosage formulation type
- “A controlled release oral dosage formulation comprising” a uniform dispersion of carbidopa and levodopa in a polymer vehicle.
- The “uniform dispersion” requirement typically matters for manufacturing and formulation structure.
B. Active ingredient amounts (per claimed unit dose)
- Carbidopa: 25–100 mg
- Levodopa: 100–400 mg
C. Polymer vehicle components and amounts
- Water-soluble polymer: 5–25 mg hydroxypropylcellulose (HPC).
- Less water-soluble polymer: 2–50 mg vinyl acetate-crotonic acid copolymer.
- The copolymer is defined by identity, not by molecular weight in your text, and is characterized by “less water-soluble.”
D. Release behavior (functional limitation)
- After administration, carbidopa and levodopa are:
- “released slowly,” and
- “simultaneously” from the formulation.
How “uniform dispersion” and “simultaneous” constrain scope
- “Uniform dispersion” narrows to systems where both drugs are distributed within the polymer vehicle such that release profiles do not depend on gross phase separation.
- “Simultaneously” is a release-time relationship constraint. In litigation, this often drives comparison studies (dissolution profile matching) and is used to argue infringement only where both actives reach comparable release timing within the claimed controlled-release window.
How narrow are US 4,900,755 dose-range claims 2 to 4?
Claims 2 to 4 are composition-specific dependent claims. They do not broaden Claim 1. They narrow it to particular dose combinations and, in Claims 3 and 4, specific polymer compositions.
Claim 2: two explicit unit doses
Claim 2 depends on Claim 1 and requires:
- Either:
- 200 mg levodopa + 50 mg carbidopa, or
- 100 mg levodopa + 25 mg carbidopa.
These amounts sit within Claim 1’s ranges and therefore fall squarely inside the independent claim envelope.
Claim 3: explicit polymer mass ratios at a higher dose
Claim 3 requires:
- 200 mg levodopa
- 50 mg carbidopa
- 5–6.5 mg vinyl acetate-crotonic acid copolymer
- about 17 mg hydroxypropyl cellulose
This is a tight set of composition parameters beyond Claim 1 because it pins both polymer masses.
Claim 4: explicit polymer mass ratios at a lower dose
Claim 4 requires:
- 100 mg levodopa
- 25 mg carbidopa
- 2.5 mg vinyl acetate-crotonic acid copolymer
- about 8.5 mg hydroxypropylcellulose
Again, it pins the polymer masses to a specific smaller-dose formulation.
What is the practical claim construction risk for “VINYL ACETATE-CROTONIC ACID COPOLYMER” language?
Because Claim 1 recites “vinyl acetate-crotonic acid copolymer” as a defined polymer identity, scope turns on whether an accused product uses the same class of copolymer as recited.
Key scope drivers
- Polymer identity: If an accused formulation uses a different enteric or hydrophobic copolymer (even if functionally similar), it may fall outside literal scope unless doctrine of equivalents is argued.
- Less water-soluble characterization: The claim text uses “less water-soluble” in describing the vinyl acetate-crotonic acid copolymer. This may affect both literal interpretation and equivalence arguments.
- Amount limits: Even if the polymer identity matches, infringement requires the recited 2–50 mg amount range (Claim 1) or pinned amounts (Claims 3–4).
What formulations are “in-scope” versus “out-of-scope” under 4,900,755?
In-scope (structural match required)
A product is most likely within scope when it meets all of these at once:
- Oral controlled-release unit dose containing carbidopa 25–100 mg and levodopa 100–400 mg.
- Both drugs are in a polymer vehicle with:
- HPC (water-soluble) in 5–25 mg, and
- vinyl acetate-crotonic acid copolymer in 2–50 mg.
- Drug release is both slow and simultaneous.
Out-of-scope (common ways to avoid Claim 1)
- Changing polymer vehicle:
- Using a different hydrophobic polymer system (examples in concept only) can avoid the “vinyl acetate-crotonic acid copolymer” identity limitation.
- Exiting the numeric composition:
- Moving HPC or the vinyl acetate-crotonic acid copolymer outside the recited ranges.
- Changing unit dose carbidopa/levodopa amounts beyond the ranges.
- Changing release mechanics:
- Using a release scheme that separates timing of carbidopa vs levodopa release, thereby failing the “simultaneously” functional requirement.
What patent landscape surrounds US 4,900,755 in controlled-release carbidopa/levodopa?
The surrounding landscape for controlled-release carbidopa/levodopa typically clusters into:
- Polymer-based controlled-release composition patents (polymer vehicle selection, ratios, and unit dose ranges)
- Method patents (manufacture, granulation, layering, dissolution tuning)
- Drug product patents (dosage form architecture, coatings, matrix systems)
- Regulatory exclusivity layers (marketing exclusivity) that interact with patent terms for generic or 505(b)(2) entrants
However, the question requires analysis tied specifically to US 4,900,755 claim scope and the patent landscape. With the only data provided being the claim text itself, a complete, accurate mapping of:
- other patents that cite/are cited by 4,900,755,
- assignees,
- expiration dates,
- Orange Book listings,
- Paragraph IV challenges,
- or specific litigation involving 4,900,755,
cannot be produced without introducing unverifiable patent-identification details.
Per the operating constraints, an incomplete or potentially inaccurate landscape answer is not provided.
How would US 4,900,755 be enforced against a generic or 505(b)(2) product?
Enforcement posture centers on composition infringement plus proof of the functional release limitation.
Infringement evidence that matters
- Bill of materials / formulation testing
- Verify polymer identities.
- Quantify HPC and vinyl acetate-crotonic acid copolymer masses per unit.
- Confirm carbidopa and levodopa per unit match the claimed ranges.
- Dissolution profile comparisons
- Establish “slowly and simultaneously” release.
- Show that both actives match timing and release kinetics within a controlled-release window consistent with the patent’s intended performance.
Design-around patterns most consistent with claim text
- Replace the hydrophobic/varying-solubility polymer component.
- Use different hydrophilic polymer identity rather than HPC (HPC is expressly named).
- Shift polymer or active dose amounts so the unit falls outside 25–100 mg carbidopa and 100–400 mg levodopa, or outside the polymer mg ranges.
What is the expected role of dependent claims 2 to 4 in litigation?
Dependent claims can materially strengthen leverage because they create harder-to-miss numerical targets.
Why Claims 3 and 4 matter
- They lock both polymer masses to specific approximate values (“about”), reducing ambiguity around whether an accused product is within or outside.
How Claim 2 fits
- Claim 2 adds two explicit unit-dose combinations that are common in practice.
- If a competitor’s marketed strengths align with those combinations, Claim 2 can become a focal point even if the competitor argues non-infringement on broader Claim 1 features.
Timeline: what claim scope implies about remaining patent value (non-assert narrative avoided)
No expiration or filing dates were provided in the prompt. A timeline with exact expiration, term adjustments, or regulatory exclusivity would require those dates and is not included.
Key Takeaways
- US 4,900,755 Claim 1 is composition-and-function specific: it requires a controlled-release oral unit dosage with uniform dispersion of carbidopa and levodopa in a vehicle combining HPC (5–25 mg) and vinyl acetate-crotonic acid copolymer (2–50 mg), with slow and simultaneous release of both actives.
- Claims 2 to 4 narrow to specific strengths and polymer compositions, making them high-value in enforcement against products matching those exact unit-dose combinations and polymer mass ranges.
- The most direct design-around is to change polymer identity (especially the vinyl acetate-crotonic acid copolymer) or to move polymer and dose quantities outside the claimed numeric bands, and/or to alter release timing so carbidopa and levodopa are not released “simultaneously” within the claimed controlled-release profile.
- A full patent landscape (citations, assignees, Orange Book status, litigation) cannot be accurately generated from the prompt’s provided data alone.
FAQs
-
What does “uniform dispersion” require for infringement under US 4,900,755?
It requires the formulation structure to distribute carbidopa and levodopa uniformly within the polymer vehicle, not as segregated phases that would change release behavior.
-
Does US 4,900,755 require the same polymer ratios across all dosage strengths?
Claim 1 gives ranges; dependent Claims 3 and 4 provide fixed composition targets for specific strengths.
-
How does the “simultaneously” release limitation affect infringement analysis?
It creates a functional timing requirement. Accused products must show that both actives release together in a controlled-release manner consistent with the claim.
-
Can a product avoid infringement by using a different hydrophobic copolymer instead of vinyl acetate-crotonic acid?
Changing polymer identity away from “vinyl acetate-crotonic acid copolymer” is the clearest route to avoiding the literal identity limitation.
-
Which claim is most important in enforcing US 4,900,755?
Claim 1 is the key because it sets the full composition plus functional release requirements; Claims 2–4 add narrower targets for specific strengths.
References
(No sources were provided or cited in the prompt; no reference list can be created without introducing external claims.)
